Skip to main content

Advertisement

SpringerLink
Log in

Stimuli Responsive In Situ Gelling Systems Loaded with PLGA Nanoparticles of Moxifloxacin Hydrochloride for Effective Treatment of Periodontitis

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The objectives of the present research work were systematic development of novel in situ gel formulation containing nanoparticles for localised delivery of moxifloxacin against bacterial periodontitis. PLGA nanoparticles were prepared and optimised in a systematic manner. Factor screening was performed with the help of half-factorial design to identify the influential factors, while response surface optimisation of the nanoparticles was conducted using central composite design. The optimum nanoparticle formulation was chosen on the basis of lower particle size, higher drug entrapment and controlled drug release characteristics up to 1 week time period, while the optimum in situ gel was selected on the basis of faster gelling and higher viscosity and gel strength properties for improved retention in the periodontium. In vivo histopathological studies and in vivo gamma scintigraphy studies revealed the extended release, superior efficacy and enhanced retention of nanoparticle-loaded in situ gelling system. Results obtained from in vivo histopathological studies after 1 week treatment with in situ gel formulation containing nanoparticles of moxifloxacin were found to be better than with 3 weeks treatment of marketed gel formulation. Overall, the studies ratify successful development of an effective site-specific drug delivery system with enhanced biopharmaceutical attributes for the periodontitis treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. AlJehani YA. Risk factors of periodontal disease: review of the literature. Int J Dent. 2014;2014:182513.

    PubMed  PubMed Central  Google Scholar 

  2. Geskovski N, Sazdovska SD, Gjosheva S, Petkovska R, Popovska M, Anastasova L, et al. Rational development of nanomedicines for molecular targeting in periodontal disease. Arch Oral Biol. 2018;93:31–46.

    CAS  PubMed  Google Scholar 

  3. Jain N, Jain GK, Javed S, Iqbal Z, Talegaonkar S, Ahmad FJ, et al. Recent approaches for the treatment of periodontitis. Drug Discov Today. 2008;13(21–22):932–43.

    CAS  PubMed  Google Scholar 

  4. Joshi D, Garg T, Goyal AK, Rath G. Advanced drug delivery approaches against periodontitis. Drug Deliv. 2014;23(2):363–77.

    PubMed  Google Scholar 

  5. Pinon-Segundo E, Ganem-Quintanar A, Alonso-Perez V, Quintanar-Guerrero D. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm. 2005;294(1–2):217–32.

    CAS  PubMed  Google Scholar 

  6. Dabhi MR, Nagori SA, Gohel MC, Parikh RK, Sheth NR. Formulation development of smart gel periodontal drug delivery system for local delivery of chemotherapeutic agents with application of experimental design. Drug Deliv. 2010;17(7):520–31.

    CAS  PubMed  Google Scholar 

  7. Mudgil M, Pawar PK. Preparation and in vitro/ex vivo evaluation of Moxifloxacin-loaded PLGA Nanosuspensions for ophthalmic application. Sci Pharm. 2013;81(2):591–606.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Guentsch A, Jentsch H, Pfister W, Hoffmann T, Eick S. Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis. J Periodontol. 2008;79(10):1894–903.

    CAS  PubMed  Google Scholar 

  9. Ardila CM, Lopez MA, Guzman IC. High resistance against clindamycin, metronidazole and amoxicillin in Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans isolates of periodontal disease. Med Oral Patol Oral Cir Bucal. 2010;15(6):947–51.

    Google Scholar 

  10. Caeiro JP, Iannini PB. Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Expert Rev Anti-Infect Ther. 2003;1(3):363–70.

    CAS  PubMed  Google Scholar 

  11. Flemmig TF, Petersilka G, Volp A, Gravemeier M, Zilly M, Mross D, et al. Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. J Periodontol. 2010;82(1):96–105.

    PubMed  Google Scholar 

  12. Swain GP, Patel S, Gandhi J, Shah P. Development of moxifloxacin hydrochloride loaded in-situ gel for the treatment of periodontitis: in-vitro drug release study and antibacterial activity. J Oral Biol Craniofac Res. 2019;9(3):190–200.

    PubMed  PubMed Central  Google Scholar 

  13. Manjunath S, Ravindra S, Ahmed M, Naveen R, Oswal S, Rangaraju V. Moxifloxacin in situ gel as an adjunct in the treatment of periodontal pocket: a clinico-microbiological study. Int J Oral Health Sci. 2018;8(1):19–25.

    Google Scholar 

  14. Shah S, Upadhyay P, Parikh D, Shah J. In situ gel: a novel approach of gastroretentive drug delivery. Asian J Biomed Pharm Sci. 2012;2(8):1–8.

    Google Scholar 

  15. Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system-an upcoming approach of gastroretentive drug delivery system. J Control Release. 2013;168(2):151–65.

    CAS  PubMed  Google Scholar 

  16. Kouchak M. In situ gelling systems for drug delivery. Jundishapur J Nat Pharm Prod. 2014;9(3):e20126-e.

    Google Scholar 

  17. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces. 2010;75(1):1–18.

    CAS  PubMed  Google Scholar 

  18. Beg S, Rahman M, Barkat M, Ahmad FJ. Nanomedicine for the treatment of disease: from concept to application. New York: Apple Academic Press; 2019.

    Google Scholar 

  19. Kranti K, Mani R, Tervankar AR. Effectiveness of subgingivally delivered 0.4% moxifloxacin gel and 0.1% oflaxacin gel in the treatment of chronic periodontitis. Int J Dent Oral Heal. 2016;2(1):8–13.

    Google Scholar 

  20. Sheshala R, Quah SY, Tan GC, Meka VS, Jnanendrappa N, Sahu PS. Investigation on solution-to-gel characteristic of thermosensitive and mucoadhesive biopolymers for the development of moxifloxacin-loaded sustained release periodontal in situ gels. Drug Deliv Transl Res. 2019;9(2):434–43.

    CAS  PubMed  Google Scholar 

  21. Beg S, Hasnain MS, Rahman M, Swain S. Chapter 1. Introduction to quality by design (QbD): fundamentals, principles, and applications. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design: Academic Press; 2019. p. 1–17.

  22. Beg S, Swain S, Rahman M, Hasnain MS, Imam SS. Chapter 3. Application of design of experiments (DoE) in pharmaceutical product and process optimization. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design: Academic Press; 2019. p. 43–64.

  23. Nayak AK, Ahmed SA, Beg S, Tabish M, Hasnain MS. Chapter 18. Application of quality by design for the development of biopharmaceuticals. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design: Academic Press; 2019. p. 399–411.

  24. Beg S, Rahman M, Panda SS. Pharmaceutical QbD: omnipresence in the product development lifecycle. Eur Pharm Rev. 2017;22(1):58–64.

    Google Scholar 

  25. Singh B, Beg S. Quality by design in product development life cycle. Chron Pharmabiz. 2013;22:72–9.

    Google Scholar 

  26. Hasnain MS, Ahmed SA, Beg S, Ansari MT, Nayak AK. Chapter 15. Quality by design approach for development of multiparticulate drug delivery systems. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design: Academic Press; 2019. p. 351–65.

  27. Swain S, Jena BR, Madugula D, Beg S, Hasnain MS. Chapter 6. Application of quality by design paradigms for development of solid dosage forms. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design: Academic Press; 2019. p. 109–30.

  28. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. AAPS J. 2008;10(2):268–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv. 2011;8(10):1341–60.

    CAS  PubMed  Google Scholar 

  31. Beg S, Hasnain MS. Pharmaceutical quality by design: principles and applications. New York: Academic Press (Elsevier); 2019.

    Google Scholar 

  32. Singh B, Beg S, Raza K. Developing “optimized” drug products employing “designed” experiments. Chem Ind Digest. 2013;23:70–6.

    Google Scholar 

  33. Negi P, Singh B, Sharma G, Beg S, Katare OP. Biocompatible lidocaine and prilocaine loaded-nanoemulsion system for enhanced percutaneous absorption: QbD-based optimisation, dermatokinetics and in vivo evaluation. J Drug Target. 2015;32(5):419–31.

    CAS  Google Scholar 

  34. Beg S, Rahman M, Kohli K. Quality-by-design approach as a systematic tool for the development of nanopharmaceutical products. Drug Discov Today. 2019;24(3):717–25.

    CAS  PubMed  Google Scholar 

  35. Beg S, Saini S, Bandopadhyay S, Katare OP, Singh B. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques. Drug Dev Ind Pharm. 2017;44(3):407–20.

    PubMed  Google Scholar 

  36. Bansal S, Beg S, Garg B, Asthana A, Asthana GS, Singh B. QbD-oriented development and characterization of effervescent floating-bioadhesive tablets of cefuroxime axetil. AAPS PharmSciTech. 2015;17(5):1086–99.

    PubMed  Google Scholar 

  37. Bansal S, Beg S, Asthana A, Garg B, Asthana GS, Kapil R, et al. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride. Drug Deliv. 2014;23(2):437–51.

    PubMed  Google Scholar 

  38. Negi P, Singh B, Sharma G, Beg S, Raza K, Katare OP. Phospholipid microemulsion-based hydrogel for enhanced topical delivery of lidocaine and prilocaine: QbD-based development and evaluation. Drug Deliv. 2014;23(3):951–67.

    PubMed  Google Scholar 

  39. Beg S, Sharma G, Thanki K, Jain S, Katare OP, Singh B. Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm. 2015;493(1–2):466–82.

    CAS  PubMed  Google Scholar 

  40. Garg V, Singh H, Bhatia A, Raza K, Singh SK, Singh B, et al. Systematic development of transethosomal gel system of piroxicam: formulation optimization, in vitro evaluation, and ex vivo assessment. AAPS PharmSciTech. 2016;18(1):58–71.

    PubMed  Google Scholar 

  41. Beg S, Raza K, Kumar R, Chadha R, Katare OP, Singh B. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium. RSC Adv. 2016;6(10):8173–87.

    CAS  Google Scholar 

  42. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913.

    CAS  Google Scholar 

  43. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69(2):445–53.

    CAS  PubMed  Google Scholar 

  44. Singh B, Raza K, Singhal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B: Biointerfaces. 2013;105:67–74.

    PubMed  Google Scholar 

  45. Koland M, Charyulu RN, Vijayanarayana K, Prabhu P. In vitro and in vivo evaluation of chitosan buccal films of ondansetron hydrochloride. Int J Pharm Investig. 2011;1(3):164–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Singh B, Kaur T, Singh S. Correction of raw dissolution data for loss of drug during sampling. Indian J Pharm Sci. 1997;59:196–9.

    CAS  Google Scholar 

  47. Singh B, Singh S. A comprehensive computer program for study of drug release kinetics from compressed matrices. Indian J Pharm Sci. 1998;60:313–6.

    Google Scholar 

  48. Pandey P, Rahman M, Bhatt PC, Beg S, Paul B, Hafeez A, et al. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine. 2018;13(8):849–70.

    CAS  PubMed  Google Scholar 

  49. Li Z, Ning W, Wang J, Choi A, Lee P-Y, Tyagi P, et al. Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res. 2003;20(6):884–8.

    CAS  PubMed  Google Scholar 

  50. Botelho MA, Martins JG, Ruela RS, Queiroz DB, Ruela WS. Nanotechnology in ligature-induced periodontitis: protective effect of a doxycycline gel with nanoparticules. J Appl Oral Sci. 2010;18(4):335–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Leite CLA, Redins CA, Vasquez EC, Meyrelles SS. Experimental-induced periodontitis is exacerbated in spontaneously hypertensive rats. Clin Exp Hypertens. 2005;27(6):523–31.

    PubMed  Google Scholar 

  52. Lima V, Vidal FDP, Rocha FAC, Brito GAC, Ribeiro RA. Effects of tumor necrosis factor—inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats. J Periodontol. 2004;75(1):162–8.

    CAS  PubMed  Google Scholar 

  53. Carvalho RS, de Souza CM, Neves JCS, Holanda-Pinto SA, Pinto LMS, Brito GAC, et al. Research effect of venlafaxine on bone loss associated with ligature-induced periodontitis in Wistar rats. J Negat Results Biomed. 2010;9(3):2–8.

    Google Scholar 

  54. Schwartz J, Connor R. Optimization techniques in pharmaceutical formulation and processing. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics. New York: Marcel Dekker, Inc.; 1996. p. 943.

    Google Scholar 

  55. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic design of experiments. Part II: retrospect and prospects. Crit Rev Ther Drug Carrier Syst. 2005b;22(3):215–93.

    CAS  PubMed  Google Scholar 

  56. Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater. 2018;73:38–51.

    CAS  PubMed  Google Scholar 

  57. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377–97.

    CAS  Google Scholar 

  58. Yang Q, Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm. 2000;26(1):61–70.

    CAS  PubMed  Google Scholar 

  59. Rahman Z, Zidan AS, Habib MJ, Khan MA. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm. 2010;389(1–2):186–94.

    CAS  PubMed  Google Scholar 

  60. Fattal E, Roques B, Puisieux F, Blanco PMJ, Couvreur P. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv Drug Deliv Rev. 1997;28(1):85–96.

    CAS  PubMed  Google Scholar 

  61. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005;22(1):27–105.

    CAS  PubMed  Google Scholar 

  62. Lutrol F127—technical information. Available online: http://www.rumapel.com.ar/pharma_excipientes/ficha_tecnica/Lutrol%20F127.pdf. Accessed 12 December 2019.

  63. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–23.

    CAS  PubMed  Google Scholar 

  64. Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev. 2008;37(8):1473–81.

    CAS  PubMed  Google Scholar 

  65. Wahl SM, Costa GL, Mizel DE, Allen JB, Skaleric U, Mangan DF. Role of transforming growth factor beta in the pathophysiology of chronic inflammation. J Periodontol. 1993;64(5 Suppl):450–5.

    CAS  PubMed  Google Scholar 

  66. Williams RC. Periodontal disease. N Engl J Med. 1990;322(6):373–82.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors also wish to acknowledge the complementary perpetual license granted by Stat-Ease Inc., USA to the author Bhpinder Singh as a part of “Pharma QbD Award” for his unparallel contribution towards QbD-based development of optimized drug delivery systems and pharmaceutical processes.

Author information

Authors and Affiliations

  1. University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, 160014, India

    Sarwar Beg, Shashi Dhiman, Teenu Sharma & Bhupinder Singh

  2. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India

    Sarwar Beg

  3. Dr. H.S. Judge Institute of Dental Science, Panjab University, Chandigarh, 160014, India

    Ashish Jain

  4. Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, 602105, India

    Rakesh Kumar Sharma

  5. UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, 160014, India

    Atul Jain & Bhupinder Singh

Authors
  1. Sarwar Beg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shashi Dhiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teenu Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ashish Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rakesh Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atul Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bhupinder Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhupinder Singh.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

ESM 1

(DOCX 206 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beg, S., Dhiman, S., Sharma, T. et al. Stimuli Responsive In Situ Gelling Systems Loaded with PLGA Nanoparticles of Moxifloxacin Hydrochloride for Effective Treatment of Periodontitis. AAPS PharmSciTech 21, 76 (2020). https://doi.org/10.1208/s12249-019-1613-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-019-1613-7

KEY WORDS

Search

Navigation